Table 5 Characteristics of patients without cancer therapy according to their vital statusa (N = 951)
From: Early mortality in lung cancer: French prospective multicentre observational study
Vital status at | |||||||
|---|---|---|---|---|---|---|---|
1 month | 3 months | ||||||
Alive | Dead | Alive | Dead | ||||
N | N = 514 | N = 437 | p-value | N = 258 | N = 693 | p-value | |
Sex | n = 514 | n = 437 | 0.071 | n = 258 | n = 693 | 0.911 | |
Men, n (%) | 733 | 384 (74.7) | 349 (79.9) | 200 (77.5) | 533 (76.9) | ||
Women, n (%) | 218 | 130 (25.3) | 88 (20.1) | 58 (22.5) | 160 (23.1) | ||
Age | n = 514 | n = 437 | <0.001 c | n = 258 | n = 693 | <0.001 | |
≤40 years, n (%) | 1 | 0 (0) | 1 (0.2) | 0 (0) | 1 (0.1) | ||
41-50 years, n (%) | 31 | 14 (2.7) | 17 (3.9) | 4 (1.6) | 27 (3.9) | ||
51-60 years, n (%) | 135 | 54 (10.5) | 81 (18.5) | 24 (9.3) | 111 (16.0) | ||
61-70 years, n (%) | 216 | 101 (19.6) | 115 (26.3) | 46 (17.8) | 170 (24.5) | ||
71-80 years, n (%) | 302 | 179 (34.8) | 123 (28.1) | 101 (39.1) | 201 (29.0) | ||
>80 years, n (%) | 266 | 166 (32.3) | 100 (22.9) | 83 (32.2) | 183 (26.4) | ||
Age | n = 514 | n = 437 | <0.001 | n = 258 | n = 693 | <0.001 | |
Mean (SD) | 74.2 (10.9) | 70.1 (11.4) | 75 (9.9) | 71.3 (11.7) | |||
Median (Q1-Q3) | 76.5 (67-82) | 71 (61-80) | 77 (69-82) | 72 (62-81) | |||
Body mass index (BMI; kg/m2) | n = 414 | n = 337 | 0.863 | n = 221 | n = 530 | 0.015 | |
Mean (SD) | 23.6 (5.1) | 23.5 (4.7) | 24.4 (5.4) | 23.2 (4.6) | |||
Median (Q1-Q3) | 23.1 (20.1-26.8) | 23.4 (20.2-26.4) | 24 (20.6-27.4) | 23 (19.9-26.2) | |||
Weight loss within the last 3 months | n = 490 | n = 394 | <0.001 | n = 249 | n = 635 | <0.001 | |
No, n (%) | 279 | 183 (37.3) | 96 (24.4) | 115 (46.2) | 164 (25.8) | ||
Yes, n (%) | 605 | 307 (62.7) | 298 (75.6) | 134 (53.8) | 471 (74.2) | ||
If yes, | n = 298 | n = 282 | 0.224 | n = 130 | n = 450 | 0.010 | |
<5 kg, n (%) | 193 | 108 (36.2) | 85 (30.1) | 56 (43.1) | 137 (30.4) | ||
5-10 kg, n (%) | 233 | 118 (39.6) | 115 (40.8) | 56 (43.1) | 177 (39.3) | ||
≥10 kg, n (%) | 154 | 72 (24.2) | 82 (29.1) | 18 (13.8) | 136 (30.2) | ||
Performance status at diagnosis | n = 511 | n = 433 | <0.001 | n = 255 | n = 689 | <0.001 | |
0- Fully active, n (%) | 65 | 54 (10.6) | 11 (2.5) | 42 (16.5) | 23 (3.3) | ||
1- Restricted in heavy physical work, n (%) | 179 | 120 (23.5) | 59 (13.6) | 78 (30.6) | 101 (14.7) | ||
2- Up and about more than half the day, n (%) | 221 | 127 (24.8) | 94 (21.7) | 59 (23.1) | 162 (23.5) | ||
3- In bed or sitting in a chair more than half the day, n (%) | 336 | 174 (34.1) | 162 (37.4) | 63 (24.7) | 273 (39.6) | ||
4- In bed or in a chair all the time, n (%) | 143 | 36 (7.0) | 107 (24.7) | 13 (5.1) | 130 (18.9) | ||
Smoking status | n = 505 | n = 427 | 0.389 | n = 252 | n = 680 | 0.174 | |
Never-smoker, n (%) | 121 | 69 (13.7) | 52 (12.2) | 37 (14.7) | 84 (12.4) | ||
Former-smoker, n (%) | 399 | 223 (44.2) | 176 (41.2) | 116 (46.0) | 283 (41.6) | ||
Active smoker, n (%) | 412 | 213 (42.2) | 199 (46.6) | 99 (39.3) | 313 (46.0) | ||
Tobacco consumption (pack-years) b | n = 394 | n = 331 | 0.822 | n = 198 | n = 527 | 0.025 | |
Mean (SD) | 47.2 (26.3) | 46.1 (22.4) | 50 (27.3) | 45.5 (23.4) | |||
Median (Q1-Q3) | 45 (30-60) | 42 (30-59) | 50 (30-60) | 42 (30-55) | |||
Tobacco duration (years) b | n = 340 | n = 280 | 0.016 | n = 172 | n = 448 | 0.012 | |
Mean (SD) | 41.9 (13.5) | 39.7 (12) | 42.9 (14.1) | 40.1 (12.3) | |||
Median (Q1-Q3) | 40 (31.8-50) | 40 (30-50) | 43 (35-50) | 40 (30-50) | |||
Histology | n = 514 | n = 437 | n = 258 | n = 693 | |||
Small-cell carcinoma, n (%) | 101 | 26 (5.1) | 75 (17.2) | <0.001 | 5 (1.94) | 96 (13.9) | <0.001 |
Adenocarcinoma, n (%) | 394 | 215 (41.8) | 179 (41.0) | 0.838 | 96 (37.2) | 298 (43.0) | 0.124 |
Squamous-cell carcinoma, n (%) | 297 | 201 (39.1) | 96 (22.0) | <0.001 | 117 (45.4) | 180 (26.0) | <0.001 |
Large-cell carcinoma, n (%) | 155 | 70 (13.6) | 85 (19.5) | 0.019 | 38 (14.7) | 117 (16.9) | 0.483 |
Adenocarcinoma in situ, n (%) | 5 | 2 (0.4) | 3 (0.7) | 0.855 | 2 (0.8) | 3 (0.4) | 0.885 c |
Carcinoid tumour, n (%) | 3 | 2 (0.4) | 1 (0.2) | 1.000 c | 1 (0.4) | 2 (0.3) | 1.000 c |
Other, n (%) | 11 | 7 (1.4) | 4 (0.9) | 0.736 | 3 (1.2) | 8 (1.2) | 1.000 c |
Genomic mutation | n = 508 | n = 430 | n = 254 | n = 684 | |||
Explored, n (%) | 195 | 110 (21.7) | 85 (19.8) | 0.530 | 55 (21.7) | 140 (20.5) | 0759 |
If explored, | n = 102 | n = 76 | n = 50 | n = 128 | |||
EGFR mutated, n (%) | 12 | 8 (7.84) | 4 (5.26) | 0.706 | 4 (8) | 8 (6.3) | 0.932 |
Stage (7 edition) | n = 502 | n = 432 | <0.001 | n = 252 | n = 682 | <0.001 | |
Stage ≤ IIB, n (%) | 94 | 79 (15.7) | 15 (3.5) | 65 (25.8) | 29 (4.3) | ||
Stage IIIA, n (%) | 99 | 75 (15.0) | 24 (5.6) | 50 (19.8) | 49 (7.2) | ||
Stage IIIB, n (%) | 88 | 51 (10.2) | 37 (8.6) | 33 (13.1) | 55 (8.1) | ||
Stage IV, n (%) | 653 | 297 (59.2) | 356 (82.4) | 104 (41.3) | 549 (80.5) | ||